Compare SNCR & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNCR | BCAB |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | United States | United States |
| Employees | 802 | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.3M | 71.6M |
| IPO Year | 2006 | 2020 |
| Metric | SNCR | BCAB |
|---|---|---|
| Price | $8.78 | $0.35 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 152.3K | ★ 2.7M |
| Earning Date | 03-10-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $170,909,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.37 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.07 | N/A |
| 52 Week Low | $3.98 | $0.24 |
| 52 Week High | $12.85 | $1.43 |
| Indicator | SNCR | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 75.33 | 35.34 |
| Support Level | $8.60 | $0.29 |
| Resistance Level | $8.73 | $0.37 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | -0.08 | 0.00 |
| Stochastic Oscillator | 68.29 | 22.36 |
Synchronoss Technologies Inc is a provider of white-label cloud, messaging, digital and network management solutions that enable its customers to keep subscribers, systems, networks and content in sync. The Synchronoss Personal CloudTM solution is designed to create an engaging and trusted customer experience through ongoing content management and engagement. The Synchronoss Personal CloudTM platform is a secure and scalable, white-label platform that allows its customers' subscribers to backup and protect, engage with, and manage their personal content. The company derives revenue from subscriptions and transaction-based fees. A majority of the firm's revenue is generated in the United States, and the rest is from countries across the world.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.